International application No.

PCT/JP2004/019753

A.	CLASSIFICATION	ON OF SUBJECT MATTER	?
----	----------------	----------------------	---

Int.Cl<sup>7</sup> A61K31/415, 31/416, 31/4162, 31/4164, 31/4155, 31/417, 31/4172, 31/4184, 45/00, A61P1/04, 9/06, 9/12, 11/02, 11/06, 13/00, 15/10, 15/12, 25/08, 25/16, 25/20, 25/22, 25/24, 25/28, 43/00,

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> A61K31/415, 31/416, 31/4162, 31/4164, 31/4155, 31/417, 31/4172, 31/4184, 45/00, A61P1/04, 9/06, 9/12, 11/02, 11/06, 13/00, 15/10, 15/12, 25/08, 25/16, 25/20, 25/22, 25/24, 25/28, 43/00,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) REGISTRY (STN), CA (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2003/030937 A1 (ONO PHARMACEUTICAL CO.,	1,2,10-15,17
A	LTD.), 17 April, 2003 (17.04.03), Particularly, page 174, line 3 to page 177, line 18; page 193; page 195, line 24 to page 199, line 24; examples 2 to 13 & EP 1438973 Al	3-9
x	WO 2003/068753 Al (ONO PHARMACEUTICAL CO.,	1,10-15,17
A	LTD.), 21 August, 2003 (21.08.03), Particularly, page 50, line 10 to page 52, line 5; page 57, line 5 to page 62, line 22; examples 1 to 44(1) (Family: none)	2-9

X	Further documents are listed in the continuation of Box C.		See patent family annex.	
* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"L"	earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
cited to establish the publication date of another citation or other special reason (as specified)		"Y"	considered to involve an inventive step when the document is	
"b"	document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"&"	combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family	
Date	of the actual completion of the international search 08 March, 2005 (08.03.05)	Date	of mailing of the international search report 22 March, 2005 (22.03.05)	
	e and mailing address of the ISA/ Japanese Patent Office	Aut	horized officer	
Facei	imile No.	Tele	phone No.	

Form PCT/ISA/210 (second sheet) (January 2004)

International application No.
PCT/JP2004/019753

Citation of document, with indication, where appropriate, of the relevant X JP 11-171865 A (Yoshitomi Pharmaceutical Industries, Ltd.), 29 June, 1999 (29.06.99), Particularly, page 69 (compounds 97, 98) (Family: none)  X US 6410533 B1 (GENZYME CORP.), 25 June, 2002 (25.06.02), Particularly, table 2 (Cmpd. No.105, 106) (Family: none)  X JP 2002-510683 A (AUSTRALIAN NUCLEAR SCIE & TECHNOLOGY ORGANIZATION), 09 April, 2002 (09.04.02), Particulaly, pages 27 to 28 & WO 1999/051594 A1  X JP 10-130150 A (Dainippon Pharmaceutical Ltd.), 19 May, 1998 (19.05.98), Particularly, page 16, left column, line page 21, left column, line 29 (Family: none)	$   \begin{array}{c}                                     $
Industries, Ltd.), 29 June, 1999 (29.06.99), Particularly, page 69 (compounds 97, 98) (Family: none)  X US 6410533 B1 (GENZYME CORP.), A 25 June, 2002 (25.06.02), Particularly, table 2 (Cmpd. No.105, 106) (Family: none)  X JP 2002-510683 A (AUSTRALIAN NUCLEAR SCIE A TECHNOLOGY ORGANIZATION), 09 April, 2002 (09.04.02), Particularly, pages 27 to 28 E WO 1999/051594 A1  X JP 10-130150 A (Dainippon Pharmaceutical A Ltd.), 19 May, 1998 (19.05.98), Particularly, page 16, left column, line page 21, left column, line 29	6,9-15,17  1-5,8 6,7,9-15,17  1,10,11 2-9,12-15,17
A 25 June, 2002 (25.06.02), Particularly, table 2 (Cmpd. No.105, 106) (Family: none)  X JP 2002-510683 A (AUSTRALIAN NUCLEAR SCIE A TECHNOLOGY ORGANIZATION), 09 April, 2002 (09.04.02), Particulaly, pages 27 to 28 & WO 1999/051594 A1  X JP 10-130150 A (Dainippon Pharmaceutical Ltd.), 19 May, 1998 (19.05.98), Particularly, page 16, left column, line page 21, left column, line 29	6,7,9-15,17  1,10,11 2-9,12-15,17  Co.,  1,10-14 2-9,15,17
A & TECHNOLOGY ORGANIZATION), 09 April, 2002 (09.04.02), Particulally, pages 27 to 28 & WO 1999/051594 A1  X JP 10-130150 A (Dainippon Pharmaceutical Ltd.), 19 May, 1998 (19.05.98), Particularly, page 16, left column, line page 21, left column, line 29	2-9,12-15,17 Co., 1,10-14 2-9,15,17
A Ltd.), 19 May, 1998 (19.05.98), Particularly, page 16, left column, line of page 21, left column, line 29	2-9,15,17

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

Box No. II

International application No. PCT/JP2004/019753 Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

1. X Cla thus is n	rnational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:  Claims Nos.: 16  because they relate to subject matter not required to be searched by this Authority, namely: im 16 pertains to methods for treatment of the human body by therapy and relates to a subject matter which this International Searching Authority ot required, under the provisions of Article 17(2)(a)(i) of the PCT and 39.1(iv) of the Regulations under the PCT, to search.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No.	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
2.	claims.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of
3.	any additional fee.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remarl	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

International application No. PCT/JP2004/019753

# Continuation of A. CLASSIFICATION OF SUBJECT MATTER (International Patent Classification (IPC))

Int.Cl<sup>7</sup> C07D495/04, 409/12, 487/04, 231/38, 231/56, 233/64

(According to International Patent Classification (IPC) or to both national classification and IPC)

## Continuation of B. FIELDS SEARCHED

Minimum documentation searched (International Patent Classification (IPC))

Int.Cl<sup>7</sup> C07D495/04, 409/12, 487/04, 231/38, 231/56, 233/64

Minimum documentation searched (classification system followed by classification symbols)

Claims 1-4, 10-15, and 17 involve an extremely large number of compounds. However, the compounds which are supported by the description in the meaning of Article 6 of the PCT and disclosed in the meaning of Article 5 of the PCT are limited to an extremely small part of the compounds claimed.

Consequently, a complete search was not made with respect to claims 1-4, 10-15, and 17. With respect to claims 5-9, a complete search was made.